Astrocyte Pharmaceuticals reports it has received a $3.0M award from the Medical Technology Enterprise Consortium. The award will support the upcoming Phase 1 human safety studies of Astrocyte’s cerebroprotectant AST-004 and the further development of a convenient oral field formulation of the drug … more
Earlier Astrocyte received a $500,000 award jointly funded by the Medical Technology Enterprise Consortium and the BrightFocus Foundation … more